|
ABEO | Abeona Therapeutics Inc. |
|
|
ABEO | Abeona Therapeutics Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 1.46 |
| Leverage | 27.49% |
| Market Cap | $ 109.3m |
| PE | 1.53 |
| Dividend Yield | 0.00% |
| Profit | $ 71.5m |
| Margin | 2733.88% |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.